Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! View ALL results for your Stocks, ETFs and Funds Screeners with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Quantum Biopharma Ltd Cls B Subordinate Voting S (QNTM.CN)

Quantum Biopharma Ltd Cls B Subordinate Voting S (QNTM.CN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [CNSX]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [CNSX]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])

Fundamentals

See More
  • Market Capitalization, $K 25,241
  • Shares Outstanding, K 5,829
  • Annual Sales, $ 0 K
  • Annual Income, $ -26,175 K
  • EBIT $ N/A
  • EBITDA $ N/A
  • 60-Month Beta 0.07
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 2.65

Price Performance

See More
Period Period Low Period High Performance
1-Month
3.0200 +43.38%
on 03/20/26
9.0000 -51.89%
on 03/30/26
+1.0800 (+33.23%)
since 03/17/26
3-Month
2.8500 +51.93%
on 03/11/26
9.4500 -54.18%
on 01/21/26
-5.6600 (-56.66%)
since 01/16/26
52-Week
2.8500 +51.93%
on 03/11/26
52.0000 -91.67%
on 06/20/25
-4.3200 (-49.94%)
since 04/17/25

Most Recent Stories

More News
Quantum BioPharma Wins Significant Court Challenge in USD $700,000,000 Claim as Defendants Joint Motion to Dismiss Lawsuit Alleging Market Manipulation by CIBC World Markets and RBC Dominion Securities is Denied

TORONTO, April 02, 2026 (GLOBE NEWSWIRE) -- Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FRA: 0K91) (“ Quantum BioPharma ” or the “ Company ”), a biopharmaceutical company dedicated to...

QNTM : 3.12 (-1.58%)
QNTM.CN : 4.3300 (+1.41%)
Quantum BioPharma Submits Investigational New Drug (IND) Application to United States Food and Drug Administration (FDA) for Lucid-MS Phase Two Clinical Trial in Multiple Sclerosis

TORONTO, April 01, 2026 (GLOBE NEWSWIRE) -- Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FRA: 0K91) (“ Quantum BioPharma ” or the “ Company ”), a biopharmaceutical company dedicated to...

QNTM : 3.12 (-1.58%)
QNTM.CN : 4.3300 (+1.41%)
Quantum BioPharma Signs Binding Letter Of Intent With Allucent To Conduct Phase 2 Clinical Trial In Multiple Sclerosis

TORONTO, March 30, 2026 (GLOBE NEWSWIRE) -- Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FRA: 0K91) (“ Quantum BioPharma ” or the “ Company ”), a biopharmaceutical company dedicated to...

QNTM : 3.12 (-1.58%)
QNTM.CN : 4.3300 (+1.41%)
Quantum Biopharma Provides Corporate Update

THIS NEWS RELEASE IS INTENDED FOR DISTRIBUTION IN CANADA ONLY AND IS NOT INTENDED FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR DISSEMINATION IN THE UNITED STATES. TORONTO, March 27, 2026...

QNTM : 3.12 (-1.58%)
QNTM.CN : 4.3300 (+1.41%)
Quantum Biopharma’s 2025 Audited Year End Financial Results Maintain ‘No Going Concern’ Status

Multiple Sclerosis Drug Candidate Lucid-21-302 Phase 1 Trial with Toxicology Studies Complete, and unbuzzd ™ Clinical Trial Published in Peer-Reviewed Journal TORONTO, March 27, 2026 (GLOBE...

QNTM : 3.12 (-1.58%)
QNTM.CN : 4.3300 (+1.41%)
Quantum Biopharma Announces Appointment of Principal Investigator for Planned Phase 2 Clinical Trial of Lucid-21-302 (Lucid-MS) in Multiple Sclerosis

TORONTO, March 26, 2026 (GLOBE NEWSWIRE) -- Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FRA: 0K91) (“ Quantum BioPharma ” or the “ Company ”), a biopharmaceutical company dedicated to...

QNTM : 3.12 (-1.58%)
QNTM.CN : 4.3300 (+1.41%)
Quantum BioPharma Announces Peer-Reviewed Journal Publication of Groundbreaking Clinical Trial With Unbuzzd

TORONTO, March 23, 2026 (GLOBE NEWSWIRE) -- Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FRA: 0K91) (“ Quantum BioPharma ” or the “ Company ”), "Company"), a biopharmaceutical company dedicated...

QNTM : 3.12 (-1.58%)
QNTM.CN : 4.3300 (+1.41%)
Quantum Biopharma Announces Closing of Initial Tranche of Private Placement Offering

THIS NEWS RELEASE IS INTENDED FOR DISTRIBUTION IN CANADA ONLY AND IS NOT INTENDED FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR DISSEMINATION IN THE UNITED STATES. TORONTO, March 20, 2026...

QNTM : 3.12 (-1.58%)
QNTM.CN : 4.3300 (+1.41%)
Quantum BioPharma Provides Corporate Update

THIS NEWS RELEASE IS INTENDED FOR DISTRIBUTION IN CANADA ONLY AND IS NOT INTENDED FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR DISSEMINATION IN THE UNITED STATES. TORONTO, March 11, 2026...

QNTM : 3.12 (-1.58%)
QNTM.CN : 4.3300 (+1.41%)
Quantum BioPharma Provides Corporate Update

THIS NEWS RELEASE IS INTENDED FOR DISTRIBUTION IN CANADA ONLY AND IS NOT INTENDED FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR DISSEMINATION IN THE UNITED STATES.   TORONTO, March 10,...

QNTM : 3.12 (-1.58%)
QNTM.CN : 4.3300 (+1.41%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 72% Sell with a Weakest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Quantum BioPharma Ltd is a biopharmaceutical company dedicated to building a portfolio of inventive assets and biotech solutions for the treatment of challenging neurodegenerative and metabolic disorders and alcohol misuse disorders with drug candidates in different stages of development. Through its...

See More

Key Turning Points

3rd Resistance Point 4.5167
2nd Resistance Point 4.4233
1st Resistance Point 4.3767
Last Price 4.3300
1st Support Level 4.2367
2nd Support Level 4.1433
3rd Support Level 4.0967

See More

52-Week High 52.0000
Fibonacci 61.8% 33.2247
Fibonacci 50% 27.4250
Fibonacci 38.2% 21.6253
Last Price 4.3300
52-Week Low 2.8500

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.